CLINICAL TRIALS PROFILE FOR ERGOCALCIFEROL

All Clinical Trials for ERGOCALCIFEROL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00114556 ↗	The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients	Completed	Novartis	Phase 4	2000-02-01	Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00114556 ↗	The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients	Completed	Royal Prince Alfred Hospital, Sydney, Australia	Phase 4	2000-02-01	Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00157066 ↗	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Completed	Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK	N/A	2002-12-01	The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 ↗	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Completed	Environmental Health Department, London Borough of Newham, London E15 4SF, UK	N/A	2002-12-01	The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 ↗	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Completed	Imperial College London	N/A	2002-12-01	The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 ↗	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Completed	Newham Chest Clinic, London E7 8QP, UK	N/A	2002-12-01	The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 ↗	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Completed	Northwick Park Hospital, Harrow, UK	N/A	2002-12-01	The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.

Clinical Trial Conditions for ERGOCALCIFEROL

Condition Name

Condition Name for ERGOCALCIFEROL
Intervention	Trials
Vitamin D Deficiency	20
Osteoporosis	4
Inflammation	3
Chronic Kidney Disease	3

Condition MeSH

Condition MeSH for ERGOCALCIFEROL
Intervention	Trials
Vitamin D Deficiency	23
Renal Insufficiency, Chronic	8
Kidney Diseases	8
Hyperparathyroidism	4

Clinical Trial Locations for ERGOCALCIFEROL

Trials by Country

Trials by Country for ERGOCALCIFEROL
Location	Trials
United States	36
Saudi Arabia	4
Thailand	3
United Kingdom	2
Canada	1

Trials by US State

Trials by US State for ERGOCALCIFEROL
Location	Trials
New York	7
Massachusetts	6
California	3
Wisconsin	3
North Carolina	2

Clinical Trial Progress for ERGOCALCIFEROL

Clinical Trial Phase

Clinical Trial Phase for ERGOCALCIFEROL
Clinical Trial Phase	Trials
Phase 4	17
Phase 3	4
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for ERGOCALCIFEROL
Clinical Trial Phase	Trials
Completed	26
Unknown status	7
Terminated	6

Clinical Trial Sponsors for ERGOCALCIFEROL

Sponsor Name

Sponsor Name for ERGOCALCIFEROL
Sponsor	Trials
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	5
Massachusetts General Hospital	3
King Faisal Specialist Hospital & Research Center	3

Sponsor Type

Sponsor Type for ERGOCALCIFEROL
Sponsor	Trials
Other	72
NIH	7
U.S. Fed	5